Abstract:Introduction: This meta-analysis aims to evaluate the efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors [PD-(L)1 inhibitors] for muscle-invasive bladder carcinoma (MIBC). Materials and methods: Four databases (Medline, Embase, Web of Science, and 21 CENTRAL) were searched for articles studying neoadjuvant PD-(L)1 inhibitors for MIBC. The search time period was from the establishment of each database to 21 July 2023. Meta-analyses of pCR, pPR, Grade≥ 3 irAEs rate, RFS, and OS were performed. Results: In total, 22 studies were included for meta-analysis. The overall pooled pCR of neoadjuvant PD-(L)1 inhibitors was 0.36 (95%CI=0.30–0.42, p=0.00). In subgroup meta-analysis, the pooled PCR of PD-(L)1 inhibitors alone, PD-(L)1 inhibitors plus other ICI, and PD-(L)1 inhibitors plus chemotherapy was 0.27 (95%CI=0.19–0.35, p=0.1), 0.41 (95%CI=0.21–0.62, p=0.01), 0.43 (95%CI=0.35–0.50, p=0.06), respectively. The overall pooled pPR of neoadjuvant PD-(L)1 inhibitors was 0.53 (95%CI=0.46–0.60, p=0.00). In subgroup meta-analysis, the pooled pPR of PD-(L)1 inhibitors alone, PD-(L)1 inhibitors plus other ICI, and PD-(L)1 inhibitors plus chemotherapy was 0.36 (95%CI=0.22–0.51, p=0.01), 0.51 (95%CI=0.39–0.62, p=0.43), and 0.61 (95%CI=0.53–0.69, p=0.01), respectively. Kaplan–Meier curves for OS and RFS were reconstructed, but there was no significant difference among three groups in terms of OS or RFS. The pooled result of Grade≥ 3 irAEs rate for neoadjuvant PD-(L)1 inhibitors was 0.15 (95%CI=0.09–0.22, p=0.00%). In subgroup analysis, the pooled result of Grade≥ 3 irAEs rate for PD-(L)1 inhibitors alone, PD-(L)1 inhibitors plus other ICI, and PD-(L)1 inhibitors plus chemotherapy was 0.07 (95%CI=0.04–0.11, p=0.84), 0.31 (95%CI=0.16–0.47, p=0.06), and 0.17 (95%CI=0.06–0.31, I 2 = 71.27%, p=0.01), respectively. Conclusion: Neoadjuvant PD-(L)1 inhibitors were feasible and safe for muscle invasive bladder cancer. Compared with PD-(L)1 inhibitors alone, PD-(L)1 inhibitors plus other ICI and PD-(L)1 inhibitors plus chemotherapy were associated with higher pCR and pPR, but higher Grade≥3 irAEs. Kaplan–Meier curves for OS and RFS indicated that neoadjuvant PD-(L)1 inhibitors had an acceptable long-term prognostic, but it was not possible to discern statistical differences between the three neoadjuvant subgroups. Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023452437, identifier PROSPERO (CRD42023452437).

Prognostic Value of Programmed Cell Death Ligand-1 Expression in Patients with Bladder Urothelial Carcinoma Undergoing Radical Cystectomy: A Meta-Analysis

The Prognostic and Clinicopathological Significance of PD-L1 Expression in Patients with Diffuse Large B-cell Lymphoma: a Meta-Analysis

Programmed Death Ligand‐1 is Associated with Tumor Infiltrating Lymphocytes and Poorer Survival in Urothelial Cell Carcinoma of the Bladder

The Prevalence and Prognostic Role of PD-L1 in Upper Tract Urothelial Carcinoma Patients Underwent Radical Nephroureterectomy: A Systematic Review and Meta-Analysis

The Clinicopathological Significance and Prognostic Value of Programmed Death-Ligand 1 in Prostate Cancer: a Meta-Analysis of 3133 Patients

The prevalence and prognostic and clinicopathological value of PD-L1 and PD-L2 in renal cell carcinoma patients: a systematic review and meta-analysis involving 3,389 patients

Prognostic Value of Preoperative Inflammation-Based Predictors in Patients with Bladder Carcinoma after Radical Cystectomy

The Vanishing Clinical Value of PD-L1 Status as a Predictive Biomarker in the First-Line Treatment of Urothelial Carcinoma of the Bladder

The Prognostic Value of Programmed Death-Ligand 1 in a Chinese Cohort with Clear Cell Renal Cell Carcinoma.

Roles of Programmed Cell Death-1/Programmed Cell Death-ligand 1 and Cytotoxic T-lymphocyte-associated Protein 4 Signaling Pathways in Bladder Urothelial Carcinoma

The Impact Of Programmed Death-Ligand 1 Expression On The Prognosis Of Early-Stage Resected Non-Small Cell Lung Cancer: A Meta-Analysis Of Literatures.

Comparison of the Prognostic Value of Ki-67 and Programmed Cell Death Ligand-1 in Patients with Upper Tract Urothelial Carcinoma

Efficacy and safety of neoadjuvant PD-1 inhibitors or PD-L1 inhibitors for muscle invasive bladder cancer: a systematic review and meta-analysis

Prognostic Value of Lymphocyte–C-Reactive Protein Ratio in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Population-Based Study

Prognostic And Clinicopathological Value Of Programmed Death Ligand-1 In Breast Cancer: A Meta-Analysis

Expression and prognostic value of PD-L1 in non-schistosoma-associated urinary bladder squamous cell carcinoma

Prognostic value of programmed cell death ligand-1 expression in breast cancer A meta-analysis

Prognostic significance of programmed cell death-ligand 1 expression on circulating tumor cells in lung cancers: systematic review and meta-analysis

Programmed Death-Ligand 1 (Pd-L1) Expression In Upper Tract Urothelial Carcinoma

The clinicopathological and prognostic value of programmed death-ligand 1 in colorectal cancer: a meta-analysis

Safety and Activity of Programmed Cell Death 1 Versus Programmed Cell Death Ligand 1 Inhibitors for Platinum-Resistant Urothelial Cancer: A Meta-Analysis of Published Clinical Trials.